SNIPR BIOME Raises EUR 35 Million Series B Financing to Advance CRISPR-Medicines Targeting Antimicrobial Resistance

COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS ("SNIPR"), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from new investors the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D) as well as existing investors Lundbeckfonden BioCapital, North-East Family Office and Wellington Partners.

This funding will support the development of a CRISPR-Cas therapy specifically targeting airway infections caused by Pseudomonas aeruginosa in people with cystic fibrosis (CF). Additionally, it will enable the advancement of a CRISPR-based microbial intervention designed to eliminate antibiotic resistance genes in humans across various bacterial species and environments. The funding will also further the clinical development of the company's CRISPR-based product, SNIPR001, in patients with hematologic cancer, including ...